人工智能在免疫治疗PET/SPECT影像中的应用
本文为范围综述,检索截至2022年10月12日的MEDLINE、CENTRAL和Embase数据库,最终纳入24篇相关文献,探讨人工智能在免疫治疗患者PET/SPECT影像中的应用。纳入队列样本量中位数(四分位距)为63(157),主要涉及肺癌、淋巴瘤和黑色素瘤,预测模型多基于影像组学或深度学习构建,主要用于预后预测或描述肿瘤表型。初步结果表明,在大型、前瞻性、多中心队列中进一步验证模型后,AI引导的免疫治疗管理具有广泛潜力。
要点
- 纳入24项研究中,肺癌占58.3%(14/24),淋巴瘤和黑色素瘤各占16.7%(4/24)。
- 预测模型多基于影像组学(50.0%,12/24)或深度学习(20.8%,5/24)构建。
- 模型最常用于预后预测(25.0%,6/24)或描述肿瘤表型(20.8%,5/24)。
核心结论
- 初步结果提示,在大型、前瞻性、多中心队列中进一步验证模型后,AI引导的免疫治疗管理具有广泛潜力。
研究设计与样本
- 范围综述,检索MEDLINE、CENTRAL和Embase数据库截至2022年10月12日,最终纳入24篇相关文献。
局限性
- 结论指出需在大型、前瞻性、多中心队列中进一步验证模型。
- 要点指出在真正转化为临床应用之前需要进一步测试。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Immunotherapy has dramatically altered the therapeutic landscape for oncology, but more research is needed to identify patients who are likely to achieve durable clinical benefit and those who may develop unacceptable side effects. We investigated the role of artificial intelligence in PET/SPECT-guided approaches for immunotherapy-treated patients.
METHODS: We performed a scoping review of MEDLINE, CENTRAL, and Embase databases using key terms related to immunotherapy, PET/SPECT imaging, and AI/radiomics through October 12, 2022.
RESULTS: Of the 217 studies identified in our literature search, 24 relevant articles were selected. The median (interquartile range) sample size of included patient cohorts was 63 (157). Primary tumors of interest were lung (n = 14/24, 58.3%), lymphoma (n = 4/24, 16.7%), or melanoma (n = 4/24, 16.7%). A total of 28 treatment regimens were employed, including anti-PD-(L)1 (n = 13/28, 46.4%) and anti-CTLA-4 (n = 4/28, 14.3%) monoclonal antibodies. Predictive models were built from imaging features using univariate radiomics (n = 7/24, 29.2%), radiomics (n = 12/24, 50.0%), or deep learning (n = 5/24, 20.8%) and were most often used to prognosticate (n = 6/24, 25.0%) or describe tumor phenotype (n = 5/24, 20.8%). Eighteen studies (75.0%) performed AI model validation.
CONCLUSION: Preliminary results suggest broad potential for the application of AI-guided immunotherapy management after further validation of models on large, prospective, multicenter cohorts.
CLINICAL RELEVANCE STATEMENT: This scoping review describes how artificial intelligence models are built to make predictions based on medical imaging and explores their application specifically in the PET and SPECT examination of immunotherapy-treated cancers.
KEY POINTS: • Immunotherapy has drastically altered the cancer treatment landscape but is known to precipitate response patterns that are not accurately accounted for by traditional imaging methods. • There is an unmet need for better tools to not only facilitate in-treatment evaluation but also to predict, a priori, which patients are likely to achieve a good response with a certain treatment as well as those who are likely to develop side effects. • Artificial intelligence applied to PET/SPECT imaging of immunotherapy-treated patients is mainly used to make predictions about prognosis or tumor phenotype and is built from baseline, pre-treatment images. Further testing is required before a true transition to clinical application can be realized.
引用
- McGale JP, Chen DL, Trebeschi S, et al. Artificial intelligence in immunotherapy PET/SPECT imaging. Eur Radiol. 2024. PMID: 38355986. doi:10.1007/s00330-024-10637-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。